These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology. Odabaşi AR; Yüksel H; Demircan SS; Kaçar DF; Culhaci N; Ozkara EE J Postgrad Med; 2007; 53(4):221-7. PubMed ID: 18097108 [TBL] [Abstract][Full Text] [Related]
9. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Devissaguet JP; Brion N; Lhote O; Deloffre P Eur J Drug Metab Pharmacokinet; 1999; 24(3):265-71. PubMed ID: 10716066 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P; Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083 [TBL] [Abstract][Full Text] [Related]
11. Estradiol-intranasal: a review of its use in the management of menopause. Dooley M; Spencer CM; Ormrod D Drugs; 2001; 61(15):2243-62. PubMed ID: 11772138 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of a new conjugated oral estrogen, estradiol-3beta-glucoside, with oral micronized 17beta-estradiol in postmenopausal women. Sweeney AT; Tangpricha V; Weinberg J; Malabanan AO; Chimeh FN; Holick MF Transl Res; 2006 Oct; 148(4):164-70. PubMed ID: 17002918 [TBL] [Abstract][Full Text] [Related]
13. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809 [TBL] [Abstract][Full Text] [Related]
14. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347 [TBL] [Abstract][Full Text] [Related]
15. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009 [TBL] [Abstract][Full Text] [Related]
16. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. van de Weijer PH; Barentsen R; de Vries M; Kenemans P Obstet Gynecol; 1999 Apr; 93(4):551-7. PubMed ID: 10214832 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic value and long-term safety of pulsed estrogen therapy. Dören M; Azzawi FA; Donnez J; Van der Mooren MJ; Villero J; Gompel A Maturitas; 2001 Jun; 38 Suppl 1():S23-30. PubMed ID: 11390121 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. von Holst T; Salbach B Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909 [TBL] [Abstract][Full Text] [Related]
19. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Stevenson JC; Rioux JE; Komer L; Gelfand M Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770 [TBL] [Abstract][Full Text] [Related]
20. Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year. Gompel A; Bergeron C; Jondet M; Dhont M; Van der Mooren MJ; Toth KS; Panay N; Von Holst T Maturitas; 2000 Oct; 36(3):209-15. PubMed ID: 11063903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]